Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Bempedoic Acid in Acute Coronary Syndrome
2021-006550-31Phase 4Active
- Sponsor
- Sociedad Española de Cardiología
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of bempedoic acid in acute coronary syndrome (ACS) and hypercholesterolemia, sponsored by Sociedad Española de Cardiología. Primary endpoint: LDL-C target achievement at 8 weeks. Started Jan 2022; status: active.
02
Drugs
bempedoic acid
03
Conditions
acute coronary syndrome (ACS)hypercholesterolemia
Beyond the preview
Go deeper on 2021-006550-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006550-31.